Condition: Locally Advanced Solid Tumor · Sponsor: Tango Therapeutics, Inc.
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
This description comes directly from the study's public registry record.
Maxim Pimpkin, MD · (857) 320-4899 · clinicaltrials@tangotx.com
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
| Grand Valley Oncology | Grand Junction, Colorado, United States | Recruiting |
| Florida Cancer Specialists & Research Institute | Lake Mary, Florida, United States | Completed |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| University Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| Carle Cancer Center | Urbana, Illinois, United States | Recruiting |
| Midwestern Regional Medical Center, City of Hope Chicago | Zion, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Cancer Center | Detroit, Michigan, United States | Recruiting |
| New York University Langone Health | New York, New York, United States | Recruiting |
| Sarah Cannon Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05732831